<p>The rapid development and global distribution of messenger ribonucleic acid (mRNA) vaccines against Coronavirus Disease 2019 (COVID-19) indicated an important shift in vaccine science and public health response. Unlike traditional vaccines that rely on live-attenuated or inactivated pathogens, mRNA vaccines use synthetic mRNA encoding the antigen, allowing host cells to produce the antigen and elicit strong immune responses. The success of mRNA vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has gradually increased global curiosity in applying this technology to treat other diseases. This review discusses the scientific basis of mRNA vaccines, including their mechanism of action, advantages in antigen design, expandable manufacturing, and modern delivery systems such as organic, inorganic, and hybrid. Beyond COVID-19, mRNA vaccines are being studied for other viral diseases, including influenza, Human Immunodeficiency Virus (HIV), Zika, and dengue. The intrinsic flexibility and speed of mRNA technology make it a valuable platform for next-generation pandemic preparedness and new therapeutic development. Despite these advantages, many challenges exist, including mRNA instability, cold-chain storage requirements, regulatory issues, and concerns regarding global vaccine availability and acceptance. Overcoming these will be critical for the full long-term potential of mRNA vaccines as a sustainable and transformative platform for global health. This review highlights recent advances, current challenges, and future perspectives of mRNA vaccine technology for viral diseases.</p>